Placebo controlled,randomised,crossover study of the efficacy of bosentan in the management of patients with Coronary Slow Flow Phenemenon

Category Primary study
Registry of TrialsANZCTR
Year 2008
INTERVENTION: Bosentan 125mgs orally twice daily for 4 weeks with 1 week washout prior to crossover CONDITION: Coronary Slow Flow Phenomenon PRIMARY OUTCOME: Angina frequency SECONDARY OUTCOME: Nitrate consumption Quality of life indices measured are Seattle Angina Questionnaire ,SF 36, Quality of Life Scale INCLUSION CRITERIA: Coronary Slow Flow Phenomenon. Angina frquency>3 episodes/week
Epistemonikos ID: 0bf664616a0bd7adfc4ce9787daeb56b25fd12f8
First added on: Aug 25, 2024